Encision Inc (ECIA) stock
ECIAOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap $163.15KP/E –Yield –
Encision r&d expenses
Research and development expenses are spending on new products and technology.
Encision's R&D Expenses for the twelve months ending Sep 30, 2025 was $665.29K, up 2.8% year over year. For fiscal 2025 it was $593.15K, down 4.6% from the year before. Over ten years it grew -7.8% a year on average. The highest annual figure on record is $1.76M in fiscal 2013.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $593.15K | -4.6% |
| FY2024 | Mar 31, 2024 | $621.89K | -23.8% |
| FY2023 | Mar 31, 2023 | $816.12K | -11.1% |
| FY2022 | Mar 31, 2022 | $918.16K | +61.2% |
| FY2021 | Mar 31, 2021 | $569.54K | -23.9% |
| FY2020 | Mar 31, 2020 | $748.39K | -4.0% |
| FY2019 | Mar 31, 2019 | $779.49K | -7.4% |
| FY2018 | Mar 31, 2018 | $842.08K | -25.3% |
| FY2017 | Mar 31, 2017 | $1.13M | -9.9% |
| FY2016 | Mar 31, 2016 | $1.25M | -6.9% |
| FY2015 | Mar 31, 2015 | $1.34M | -4.6% |
| FY2014 | Mar 31, 2014 | $1.41M | -19.9% |
| FY2013 | Mar 31, 2013 | $1.76M | +30.1% |
| FY2012 | Mar 31, 2012 | $1.35M | -7.8% |
| FY2011 | Mar 31, 2011 | $1.46M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $201.39K | +29.5% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $165.44K | +18.9% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $159.65K | -20.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $138.80K | -8.1% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $155.52K | +54.2% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $139.18K | -17.4% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $201.54K | +15.1% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $151.08K | -39.0% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $100.85K | -54.8% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $168.42K | -1.2% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $175.03K | -47.6% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $247.57K | +27.5% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $223.05K | +4.6% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $170.47K | -3.6% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $333.99K | +164.9% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $194.12K | +39.3% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $213.16K | +31.2% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $176.88K | +24.9% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $126.09K | -30.2% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $139.39K | -12.3% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $162.46K | -5.9% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $141.61K | -40.0% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $180.64K | -23.7% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $158.94K | -16.1% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $172.67K | -7.5% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $236.14K | +41.7% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $236.89K | +14.5% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $189.35K | -15.5% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $186.58K | -1.7% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $166.67K | -24.7% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $206.92K | -15.8% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $223.98K | -25.4% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $189.86K | -31.9% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $221.33K | -26.6% |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $245.87K | -23.3% |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $300.39K | -11.6% |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $278.72K | – |
| Q1 FY2017CQ2 2016 | Jun 30, 2016 | $301.65K | – |
| Q4 FY2016CQ1 2016 | Mar 31, 2016 | $320.39K | – |
| Q3 FY2016CQ4 2015 | Dec 31, 2015 | $339.75K | – |
See a number that looks wrong?